YIH
IMGN

Y-Intercept (HK)’s Immunogen Inc IMGN Stock Holding History

Y-Intercept (HK)’s Portfolio IMGN Stock Details IMGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-14,325
Closed -$68.5K – 1439
2022
Q3 		$68.5K Buy
+14,325
New +$75.5K 0.01% 903
2021
Q1 		– Sell
-10,986
Closed -$73K – 861
2020
Q4 		$73K Buy
+10,986
New +$64.1K 0.03% 488

Other funds holding IMGN

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Y-Intercept (HK)'s IMGN Position: Q4 2022 in Review

Y-Intercept (HK) sold out of Immunogen Inc (IMGN) in Q4 2022, closing a stake of 14,325 shares — an estimated $68.5K sold.

Y-Intercept (HK) first reported a position in IMGN in Q4 2020 and held it in 2 quarters. The position peaked at $73K in Q4 2020. 204 funds tracked by Wall St. Rank hold IMGN as of Q4 2022.

  • Y-Intercept (HK) reported no remaining Immunogen Inc position as of Q4 2022 after selling out during the quarter.
  • Y-Intercept (HK) sold 14,325 Immunogen Inc shares in Q4 2022, an estimated $68.5K.
  • Y-Intercept (HK) first reported a position in Immunogen Inc in Q4 2020 and held it in 2 quarters.
  • Y-Intercept (HK)'s Immunogen Inc position peaked at $73K in Q4 2020.
  • 204 funds tracked by Wall St. Rank held Immunogen Inc as of Q4 2022.

Based on Y-Intercept (HK)'s 13F filing for Q4 2022, filed 14 Feb 2023.